Skip to search formSkip to main contentSkip to account menu

177Lu-PSMA-617

Known as: 177Lu-617-prostate-specific membrane antigen ligand 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DipeptidesHeterocyclic Compounds, 1-Ring

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Re: Long Term Follow-up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant…
2016
2016
Investigation of a hybrid image approach and a reduction in the number of blood samples for a decreased clinical workload for patient-specific bone marrow dosimetry in Lu-177-DKFZ-PSMA-617 therapy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)